Kornimate/medical-research-clean huggingface dataset:
lmwh compliance in pregnancy

Conditions: Venous Thromboembolism; Antenatal Deep Vein Thrombosis

Summary: this is a prospective chart study that will aim to assess objective data on compliance levels to low molecular weight heparin (lmwh) injections among pregnant and postnatal women undergoing vte thromboprophylaxis treatment at cork university maternity hospital. this is a study that will help shine light on accurate data for compliance and possible factors affecting it, which will be useful for more individualised treatment plans for future patients. patients at higher risk of venous thromboembolism undergoing vte thromboprophylaxis will be invited to participate in the study. once the patient reads the information leaflet and signs consent, data will then be collected from the patients medical record. the patient will be given a smart sharps bin with an individual, unique product code. this device will be provided by healthbeacon, a dublin based start-up company. the device will be personalised with the treatment schedule pre-loaded onto it. when a used lmwh injection is disposed into the smart sharps bin, an infrared sensor is activated. the system captures an image of the injection in the chamber before moving it to the normal 'sharps' container of the bin for disposal. the captured image is time-stamped and sent to healthbeacon's electronic database. healthbeacon will only have the data pertaining to the disposal of injections for each sharps bin (i.e. the timing of the disposal of each used injection in each pre-coded bin). we are blinded to the compliance information and will only will receive the raw data once treatment is completed. data will be analysed to determine compliance of lmwh injections. this study will enable us to have a better insight on accurate compliance rates for lmwh injections in pregnant women at higher risk for venous thromboembolism (vte). understanding compliance with lmwh injections and the factors which can affect it, will hopefully guide future information and education that we offer to patients who are prescribed lmwh injections and help decrease maternal mortality rates in future.


Eligibility criteria:
inclusion criteria: * current vte * previous history of vte * class iii obesity * history of placenta mediated complications * pre-eclampsia * advanced maternal age * inherited thrombophilia * prolonged immobilization * varicose veins * other risk factors that predispose them to vte exclusion criteria: * life-long anti-coagulation * mechanical heart valves * other forms of injectable therapy for other illnesses * long-term severe physical disability affecting mobility (eg: paraplegia, paralysis

Keywords: pregnancy thromboprophylaxis lmwh compliance
a study of the safety and pharmacokinetics of gdc-0152, administered intravenously to patients with locally advanced or metastatic malignancies

Conditions: Solid Cancers

Summary: the study consists of two stages. in stage 1, maximum tolerated dose (mtd) will be determined. in stage 2, additional patients will be treated at the mtd of gdc-0152.


Eligibility criteria:
inclusion criteria * histologically documented, incurable, locally advanced or metastatic solid malignancies, or non-hodgkin's lymphoma (nhl) without leukemic phase * disease (either target or non-target lesions) that can be assessed by imaging studies and/or physical examination * for patients with solid tumors or nhl without leukemic phase, disease progression on or after standard therapy, or a malignancy for which there is no standard therapy * all prior therapy-related toxicities have recovered to baseline-grade toxicity with the exception of alopecia. * life expectancy of ≥ 60 days * resting oxygen saturation ≥ 92% on room air * agreement to use an effective form of contraception for the duration of the study exclusion criteria * history of central nervous system disease * chemotherapy, cancer hormonal therapy (except gnrh agonists), radiotherapy, or immunotherapy within 4 weeks prior to day 1 (6 weeks for nitrosoureas or mitomycin) * use of any other investigational agent or device * major surgery or significant traumatic injury within 3 weeks prior to day 1 * pregnant or nursing * clinically significant cardiovascular disease, new york heart association (nyha) classification grade 2 or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade 2 or greater peripheral vascular disease on day 1 * known hiv infection * patients with ongoing inflammatory processes or a grade ≥ 2 fever or grade ≥ 2 fever-associated constitutional symptoms (including rigors/chills, sweating, and others determined by the investigator), or a clinically significant systemic infection within the last month * any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications * history of any chronic liver disease, active hepatic infection, or evidence of hepatic cirrhosis, or grade ≥ 2 liver dysfunction. * baseline oxygen requirement or history of pulmonary fibrosis * any signs or symptoms grade ≥ 2 by national cancer institute common terminology criteria for adverse events, version 3.0, at study entry except for alopecia, pain, asymptomatic grade 2 diffusing capacity of the lung for carbon monoxide (at the discretion of the investigator) or where otherwise specified * patients who need to take a concomitant medication, dietary supplement, or food that is a known inhibitor/inducer of the cyp3a4/5 and/or the 2c8 metabolic pathway or that has a narrow therapeutic window and involves these enzymes for their metabolism

Keywords: gdc0152 iap iap antagonist
semi-closed loop automated insulin therapy in the pediatric population aged 2-6 years with type 1 diabetes: impact on quality of life and glycemic control

Conditions: Type 1 Diabetes; Closed Loop; Insulin; Quality of Life; Pediatric

Summary: the incidence of type 1 diabetes is increasing, with an incidence of +4% per year in france today. the treatment for type 1 diabetes is insulin therapy. in recent years, new systems have emerged, so-called "semi-closed loop" systems, also called automated insulin therapy, which have proven their superiority in terms of quality of life and glycemic balance in adults and children over 6 years old. since january 24, 2024, the has now recognizes the indication of the semi-closed loop for the ypsopump model in children aged 2 to 6 years. this is the first reimbursement in france of a closed loop system for the 2-6 year old age group. there are currently few studies comparing the quality of life of children in semi-closed loop versus other treatments (open loop or injections). regarding quality of life, the studies found mainly concern the contribution for parents and the improvement of adolescents' sleep as in the study by erin c cobry et al from 2020 (6). our study therefore aims to demonstrate an improvement in quality of life but also in diabetes balance in type 1 diabetic patients on a closed loop insulin pump versus open loop or injections in the pediatric population aged 2-6 years.


Eligibility criteria:
inclusion criteria: * -patients aged 2 to 6 years inclusive * presenting type 1 diabetes on insulin therapy * social security affiliates * patient initiating semi-closed loop treatment * family (at least one parent or representative of parental authority) agreeing to follow the training necessary for continuous measurement of glucose in real time. * collection of non-opposition from one of the two parents or the representative of parental authority agreement exclusion criteria: * opposition to participation in research involving humans or opposition to the use of data or samples and associated data (withdrawal of non-opposition).

Keywords: closed-loop insulin therapy type 1 diabetic quality of life pediatric patient
copenhagen study of obese patients with ischemic heart disease undergoing low energy diet or interval training

Conditions: Ischemic Heart Disease; Obesity

Summary: the purpose of the study is to make a head-to-head comparison of weight loss and interval training as methods of secondary prevention in overweight patients with ischemic heart disease.

in western countries 80 % of patients with ischemic heart disease (ihd) are overweight (bmi \> 25). weight loss using a low energy diet (led, 800 - 1000 kcal/day) has been shown to induce a considerable weight loss in obese but otherwise healthy patients and to reduce the risk of cardiovascular disease and diabetes in these subjects. additionally, a british study using a very low energy diet (vled, 600 kcal/day) to obtain weight loss, has shown that subject with diagnosed type 2 diabetes had their blood glucose normalized after an 8 week vled. however, the effect of led has never been examined in overweight patients with ihd. several studies have shown that patients with ihd have a beneficial effect of exercise training regarding mortality and reduction in cardiovascular risk factors. a norwegian group has shown that aerobic interval training results in the biggest increase in maximal oxygen uptake (vo2max). a high vo2max is correlated to decreased mortality in patients with ihd. in conclusion, weight loss and exercise are known strategies in preventing progression of ihd and development of type 2 diabetes in these patients, however a head-to-head comparison of the two methods has never been made and it is unknown which intervention is the most effective in improving cardiovascular risk profile. furthermore, several mechanisms behind the known beneficial effect of these interventions are unknown.

Eligibility criteria:
inclusion criteria: * stable ischemic heart disease * bmi 28 - 40 kg/m2 exclusion criteria: * known diabetes mellitus * repeated fasting plasma glucose ≥ 7 mmol/l or hba1c \> 7 % * severe or moderate valve disease * main stem stenosis * severe heart failure, ejection fraction \< 35 % * physical or mental disability which are expected to prevent completion of intervention * severe chronic obstructive pulmonary disease (copd) (fev1 \< 50 % of expected) or asthma * active cancer * severe kidney (gfr \< 40 ml/hour) or severe liver disease * severe ischemia or arrhythmias during exercise test * 2. or 3. degree atrio-ventricular (av) block, not protected by pacemaker * organised training more than 2 times a week prior to inclusion * significant weight loss or weight gain (\> 5 %)3 month prior to inclusion * not able to comprehend written and oral informed consent * hormone treatment

Keywords: interval training weight loss secondary prevention rehabilitation cardiovascular risk factors
efficacy testing of melon oil olive pressed candy products

Conditions: Skin Condition

Summary: to assess melon and oil olive pressed candy on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged above 18 years old * ita° value 20°-41° exclusion criteria: * involuntary subjects. * subjects who have a history of skin diseases such as psoriasis, eczema, atopic dermatitis, severe acne; or suffer from other chronic systemic disease. * those with known cosmetic, drug or food allergies. * female who is pregnant or nursing or planning to become pregnant during the course of the study. * subjects who have taken oral or topical corticosteroids and other anti-inflammatory drugs in the past 1 month. * use of any products or drugs that affect skin color such as fruit acid, salicylic acid (such as hydroquinone preparations) in the past 2 months. * in the past 3 months, the test site has used retinoic acid preparations or undergone chemical peeling, laser, pulse light and other medical aesthetic therapists * subjects who can not avoid long-term sun exposure
ultrasonic weaning criteria in prolonged ventilation

Conditions: Acute Respiratory Distress Syndrome

Summary: compare and evaluate the effect of use of ultrasonic criteria of weaning versus the conventional ways of weaning in post-traumatic acute respiratory distress syndrome (ards) patients who were ventilated for a long time. and compare their effect on the duration of icu stay.

it is a prospective double blind study done on total 200 patients. who were weaned from ventilator after being ventilated for \> one week due to respiratory failure. this respiratory failure was selected in our study to be from severe lung contusion and post-traumatic acute respiratory distress syndrome. patients were randomly allocated in one of two groups each group contain 100 patients. group a considered control group. those patients weaned from the ventilator by the conventional criteria of weaning. while group b weaned from the ventilator by the ultrasound criteria of weaning. all patients weaned from both groups followed for six days for signs of failure of weaning ,signs of post-extubation respiratory failure. and number of patients who were re-ventilated and who discharged from icu in both groups recorded and compared.

Eligibility criteria:
inclusion criteria: * adult patients between 18-65 years old, * with acute respiratory distress syndrome, * any ventilated patients for more than one week exclusion criteria: * young or pediatric patients below 18 years. * patients older than 65 years * patients had chronic respiratory disease
effects of gene polymorphisms on metabolic features in clozapine-treated patients with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in taiwan.

the atypical antipsychotics, such as olanzapine, risperidone, quetiapine, and ziprasidone, are effective in treating both the positive and negative symptoms in schizophrenia (kelleher et al., 2002). however, atypical antipsychotics have been linked to several forms of morbidity, including obesity, hyperlipidemia, and type 2 diabetes mellitus (dm) (bergman and ader, 2005; jin et al., 2004; melkersson and dahl, 2004). compared with the general population, life expectancy in schizophrenic patients is shorter by as much as 20%, attributable to higher rates of suicide, accidental deaths, and natural causes such as cardiovascular disease and dm (harris and barraclough, 1998). several studies have suggested that these metabolic abnormalities may lead to a greater vulnerability to cardiovascular disease and thus may contribute to the excessive mortality among schizophrenic patients.

Eligibility criteria:
inclusion criteria: * fulfilled dsm-iv criteria of schizophrenia or schizoaffective disorder * 18-65 year of age * receiving clozapine for at least 6 months exclusion criteria: * diabetes mellitus patients

Keywords: schizophrenia schizoaffective disorder
evaluation of the gore® viabahn® balloon expandable endoprosthesis (viabahn bx)

Conditions: Common Iliac Artery Occlusive Disease; External Iliac Artery Occlusive Disease; Peripheral Arterial Disease

Summary: the primary objective of the vbx13-05 clinical study is to evaluate the safety and efficacy of viabahn bx for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or external iliac arteries.


Eligibility criteria:
inclusion criteria: * patient is at least 18 years old; * patient is male, infertile female, or female of childbearing potential practicing an acceptable method of preventing pregnancy; * patient or legal representative is willing to give written informed consent; * patient is capable of complying with protocol requirements, including all follow-up visits; * patient has symptomatic claudication or rest pain without tissue loss (rutherford categories 2-4). * patient has de novo or restenotic target lesion(s) in the common and/or external iliac artery exclusion criteria: * patient has a life expectancy of less than 1 year; * patient has a known allergy to stent graft components, including stainless steel or heparin; * patient has a known intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would prevent compliance with the protocol; * patient has a condition (unrelated to the study) that is expected to require indefinite, or lifelong, anticoagulation * patient has had vascular access / catheterization in the lower extremity within 30 days of study enrollment; * patient has had a previous or planned coronary intervention within 30 days prior to enrollment in this study or required at time of study procedure; patient has had a previous or planned bypass surgery in the target leg, or a bypass that occurs at the time of the study procedure; * patient is currently participating in this or another investigative clinical study. * patient has evidence of angiographically visible thrombus within or adjacent to the target lesion(s); * patient has aneurysmal dilation proximal or distal to the target lesion(s) that would interfere with the placement of the device; * patient has a target lesion requiring atherectomy or any ablative device to facilitate stent delivery; * patient has a target lesion situated in such a way that an implanted device will prevent blood flow or perfusion to the internal iliac artery if patent

Keywords: pad stent claudication viabahn gore endoprosthesis vascular diseases cardiovascular diseases iliac occlusive disease balloon expandable stent graft vbx
ambulation for latency during expectant management of pprom

Conditions: Preterm Premature Rupture of the Membranes; Pregnancy Complications; Pregnancy, High Risk

Summary: ambulation in pregnancy has been proposed to decrease stress and anxiety, increasing preterm birth. whether ambulation is causally related to latency is unknown. the fitbit will be used for tracking the number of steps taken daily by each participant, and for encouraging the intervention group to walk. the fitbit is the most widely used physical activity tracker in medical research, and its use has been validated for research use in pregnant women. the purpose of the study is to evaluate whether ambulation in patients with preterm premature rupture of the membranes (pprom) prolongs latency.


Eligibility criteria:
inclusion criteria * pregnant women aged 12-55 * gestational age 23 0/7 to 35 0/7 weeks * pprom confirmed by clinical diagnosis which includes sterile speculum examination with pooling, ferning, and nitrazine tests, or the amnisure rom test * planned inpatient expectant management with delivery goal \>=7 days from enrollment * ability to provide informed consent in english or spanish exclusion criteria * imminent delivery * transverse or footling breech presentation (if multiple gestation, presenting fetus) * unstable lie (if multiple gestation, presenting fetus) * funic presentation (if multiple gestation, presenting fetus) * active vaginal bleeding * regular, painful contractions (\>=3 in 10 minutes for 30 minutes or more) consistent with labor * clinical contraindication to ambulation as determined by the managing physician * physician declines to have the patient approached for participation * lethal fetal anomalies

Keywords: pregnancy pprom
chromatic retinal stimulation to reduce chronic pain and pain sensitivity

Conditions: Chronic Low-back Pain; Chronic Pain; Fibromyalgia

Summary: participants with chronic pain conditions including chronic low back pain and fibromyalgia may benefit from light stimuli presented to the retina to reduce chronic pain severity and pain sensitivity. participants will be recruited into this study and will be presented with one of three uniform light stimuli via a wide-field ganzfeld in three conditions to determine the retinal mechanisms that reduce pain. this work will lead to a greater understanding of retinal mechanisms that contribute to pain and will assist the design of future studies to harness the potential of light based pain therapies.


Eligibility criteria:
inclusion criteria: * adults greater than or equal to 18 and less than or equal to 65. * individuals who have been diagnosed with fibromyalgia or chronic low back pain by their physician. * individuals who experience an average pain severity greater than 4/10 in intensity at baseline. * willingness to wear a battery-operated portable ganzfeld light stimulator device for 2 hours per day at the same time each day (ideally complete the light therapy session between 5 am-10 am each morning) for 5 days. * alert and oriented, and able to provide informed consent * ability to read and speak english to complete validated questionnaires. exclusion criteria: * vision disorders or conditions resulting in severe vision impairment or blindness * individuals with self-report of color blindness * prisoner status * pregnancy * no other history or condition that would, in the investigator's judgment, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger the patient). * history of seizure disorder
the effect of doxycycline on matrix metalloproteinase expression and activity in the abdominal aneurysm

Conditions: Aortic Aneurysm, Abdominal

Summary: the matrix metalloproteinase-9 (mmp-9) is considered to play a central role in abdominal aortic aneurysm (aaa) initiation. doxycycline has direct mmp-9 inhibiting properties in vitro, and it effectively suppresses aaa development in rodents. observed inhibition of aaa progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall mmp-9 suggest that the effects of doxycycline extend beyond mmp-9 inhibition, and that the effect may be dose dependent.

in this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective aaa repair. the effect of doxycycline treatment on mmp and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.

Eligibility criteria:
inclusion criteria: * elective open aneurysm repair exclusion criteria: * severe kidney and liver dysfunction

Keywords: collagenases mmp cathepsins doxycycline aneurysm
oxygen delivery during cardiopulmonary bypass and inflammatory reaction after cardiac surgery

Conditions: Cardiopulmonary Bypass; Cardiac Surgery; Systemic Inflammatory Response Syndrome (SIRS)

Summary: cardiac surgery, especially when involving cardiopulmonary bypass (cpb), has long been associated with a systemic inflammatory response that can lead to a range of complications, from mild symptoms to severe organ dysfunction, and mortality. the exact mechanisms behind this response remain a topic of extensive research, but it's clear that the body's reaction to the extracorporeal circulation, combined with surgical trauma, plays a significant role. factors such as genomics, age, specific preoperative conditions, and the duration of operations have been associated with significant clinical responses. a pivotal insight into this response comes from recent genome-wide transcriptional analyses. perioperative ischemia and ischemia-reperfusion injury (iri) have been suggested as hub-nodes in a hierarchic structure evaluating the response to cardiac surgery. this suggests that iri isn't just a side effect of the surgery but might be a central player in the body's inflammatory response. the role of perioperative ischemia and its potential as a significant contributor to the postoperative inflammatory response cannot be understated. this study aims to delve deeper into the role of oxygen delivery and its implications in the systemic inflammatory response post- cardiac surgery.


Eligibility criteria:
inclusion criteria: * adult patients (18-90 years) * elective surgery * cpb-assisted exclusion criteria: * age \ 90 years * infective endocarditis * hypothermia during surgery (\<34°c) * emergency surgery

Keywords: cardiopulmonary bypass oxygen delivery systemic inflammatory reaction syndrome cardiac surgery